Results 41 to 50 of about 461 (125)

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source

Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity. Materials and Methods The phase 3a, 68‐week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity‐related complication, to once‐weekly CagriSema 2.4 mg/2.4 ...
Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen, Timothy W. Garvey, Deborah B. Horn, Barbara McGowan, Claire Prener Miller, Volker Schnecke, Carel W. le Roux   +8 more
wiley   +1 more source

QBP1 Peptide as a Potential Anti‐Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study

Advanced Science, Volume 13, Issue 37, 3 July 2026.
The anti‐amyloidogenic peptide QBP1 effectively halts human islet amyloid polypeptide (hIAPP) aggregation, preventing the formation of toxic β‐structured intermediates. Through a combination of biophysical assays, molecular dynamics, and cell‐based studies, QBP1 is shown to preserve β‐cell viability and metabolic homeostasis, positioning it as a ...
María M. Tejero‐Ojeda, Ada Bernaus Vives, Michał Wojciechowski, Dinh Quoc Huy Pham, Mateusz Chwastyk, Mario Vallejo, Anna Novials, Douglas V. Laurents, Mariano Carrión‐Vázquez   +8 more
wiley   +1 more source

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

Indian Journal of Endocrinology and Metabolism
Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the ...
Wael R. Sidrak, Sanjay Kalra, Atul Kalhan   +2 more
doaj   +1 more source

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines [PDF]

GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0?mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6?8%, Semaglutide 2.4?mg once weekly improved weight loss to about 12?15%,
Holst, Jens J, Madsbad, Sten
core   +1 more source

Perspectivas innovadoras en el tratamiento de la obesidad

Revista de la Sociedad Argentina de Diabetes
El tratamiento de la obesidad atraviesa un cambio paradigmático impulsado por el desarrollo de terapias hormonales estimuladas por nutrientes, por la eficacia en la reducción del peso (15-25%) que se aproxima a la obtenida con la cirugía bariátrica, y ...
María Yuma
doaj   +1 more source

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers ...
Stefan D. Anker, Linong Ji, Tammy Kindel, Andrew J. S. Coats, Dike Ojji, Adriana Puente Barragán, Peter Rossing, Shelley Zieroth, Shaaf Ahmad, Shariq Usman, Geeta Appannah, Alison L. Bailey, Ahmed Bennis, Andrea Brandao, Javed Butler, Melanie J. Davies, Lubomira Fabryova, Yuan‐Lin Guo, Hidetaka Itoh, Uday M. Jadhav, Carel W. Le Roux, Fausto J. Pinto, Julio Rosenstock, Banshi Saboo, Hani Sabbour, Mangesh Tiwaskar, Karol E. Watson, Kwang Wei Tham, Fernando Stuardo Wyss, Walter P. Abhayaratna, William T. Abraham, Wael Al Mahmeed, Alessia Argirò, John J. Atherton, Danielle Belardo, Raquel Campuzano, Nandini Chatterjee, Marc‐André Cornier, Sarah Davies, Clemencia de Rueda Panadero, Anastase Dzudie, Ty J. Gluckman, Muhammad Shahzeb Khan, Kamlesh Khunti, Yuri Lopatin, Zhiyi Ma, Okechukwu S. Ogah, Abraham Oomman, Emilio S. Peralta Lopez, Ping Li, Paul Poirier, Julie Redfern, Giuseppe M. C. Rosano, Donna Ryan, Amit Saraf, Sameh Shaheen, Subodh Verma, Stephan von Haehling, Martha Gulati, Naveed Sattar, Jose Luis Zamorano   +60 more
wiley   +1 more source

Metabolic and appetitive regulation of adipocyte mass during treatment of obesity

Journal of Internal Medicine, Volume 299, Issue 1, Page 66-78, January 2026.
Abstract Adipose mass is homeostatically maintained within a narrow range despite fluctuations in daily calorie intake and activity levels. Constituting an adipose mass “set point,” this homeostatic regulation includes sensing mechanisms in the form of hormones reflecting caloric intake that serve as mediators of appetitive behaviors and adipose mass ...
Jonathan Q. Purnell, Carel W. Le Roux
wiley   +1 more source